Aichi Cancer Center
Designated by the Minister of Health, Labour and Welfare as a hub hospital for cancer genome medical care.
 Cancer Genomic Medicine
A form of treatment for cancer based on genomic alterations/profiles, which offers medical professionals more effective treatment plans using of therapeutic drugs selected based on genomic variants/profiles to deliver “precision medicine,” tailored to individual patients
 The joint research, which builds on Fujitsu’s recent collaborative efforts with the Institute of Medical Science at the University of Tokyo and AI technologies cultivated by Fujitsu Laboratories
In a joint research project with the Institute of Medical Science at the University of Tokyo, Fujitsu Laboratories Ltd. has developed AI technology that makes the examination of treatment policies for acute myeloid leukemia more efficient and precise. The project utilizes a database developed by Fujitsu Limited in cooperation with the Japan Agency for Medical Research and Development as part of the "Program for an Integrated Database of Clinical and Genomic Information.” Details in the following press release: https://www.fujitsu.com/global/about/resources/news/press-releases/2019/1106-01.html
 Multigene Panel Testing for Cancer
Multigene panel testing is transforming clinical management of patients with cancer. The Japanese government approved reimbursement of two cancer genome profiling systems under universal health coverage in June 2019. These testing systems promise to play an important role in the expansion of the emergent field of cancer genomic medicine.
Fujitsu is the leading Japanese information and communication technology (ICT) company, offering a full range of technology products, solutions, and services. Approximately 132,000 Fujitsu people support customers in more than 100 countries. We use our experience and the power of ICT to shape the future of society with our customers. Fujitsu Limited (Code: 6702) reported consolidated revenues of 4.0 trillion yen (US $36 billion) for the fiscal year ended March 31, 2019. For more information, please see www.fujitsu.com.
Founded in 1968 as a wholly owned subsidiary of Fujitsu Limited, Fujitsu Laboratories Ltd. is one of the premier research centers in the world. With a global network of laboratories in Japan, China, the United States and Europe, the organization conducts a wide range of basic and applied research in the areas of Next-generation Services, Computer Servers, Networks, Electronic Devices and Advanced Materials. For more information, please see: http://www.fujitsu.com/jp/group/labs/en/.
Aichi Caner Center is one of the largest and oldest comprehensive cancer centers in Japan. For more than 50 years, the Aichi Cancer Center has been a leader in cancer research and treatment, offering state-of-the art care available and advancing the knowledge for future improvement. Our dedicated clinical and research staff, who are working passionately and collaboratively, are relentlessly committed to providing hope to currently uncurable patients and making cancer a disease of the past. For more information, please see: https://www.pref.aichi.jp/cancer-center/english/cc/index.html.
Technical ContactsArtificial Intelligence Laboratory
Company:Fujitsu Laboratories Ltd.
Technical ContactsRisk Assessment Center
Company:Aichi Cancer Center Hospital
Press ContactsPublic and Investor Relations Division
Press ContactsDivision of Management Strategy, Administration Office
Company:Aichi Cancer Center
All company or product names mentioned herein are trademarks or registered trademarks of their respective owners. Information provided in this press release is accurate at time of publication and is subject to change without advance notice.
Date: 29 November, 2019
Company: Fujitsu Laboratories Limited ,Aichi Cancer Center